Early viral complications after autologous CD34-selected peripheral blood stem cell transplantation
We considered of great clinical significance a recent report from Holmberg et al 1 on the increased incidence of CMV disease after autologous CD34-selected peripheral blood stem cell (PBSC) transplantation. We reported previously an increased incidence of viral complications after autologous CD34-selected PBSC transplantation in 19 consecutive patients. 2 We recently analyzed a cohort of 40 CMVseropositive patients affected by hematological malignancies submitted to CD34-selected PBSC. CD34 selection was carried using the Ceprate SC (Cellpro, Bothell, WA, USA) in 25 patients and CliniMACS (Miltenyi Biotec, Bergisch-Gladbach, Germany) in 15 patients thereafter, both according to the manufacturer's specifications and we retrospectively evaluated the incidence of CMV disease and other viral complications within the first 100 days after transplantation. Results were compared to a cohort of 136 CMV-seropositive patients submitted to unfractionated PBSC and treated at the same institution over a period of 5 years. Overall 31 patients (77.5%) submitted to CD34-selected PBSC transplantation had weekly CMV screening studies performed including the CMV pp65 antigenemia assay (CMV Brite; Biotest Diagnostic Corp, Denville, NJ, USA) and viral culture monitoring from stools, urine and throat were performed weekly in 30 patients. CMV infection was defined as either the evidence of any level of quantitative pp65 antigenemia and/or a positive culture. CMV disease was defined as a conventional culture of bronchoalveolar lavage fluid, or gastric/duodenal biopsy in association with symptoms. 3 Other viral infections were defined as the evidence of positive culture from urine, stools or throat in association with symptoms. Of the 40 patients, 39 were transplanted for hematological malignancies (97.5%) including NHL, MM and HD. The median number of CD34 + × 10 6 /kg infused was 4.2 (0.86-16). The characteristics of the patients are shown in Table 1 . Of the 136 patients transplanted with unfractionated PBSC, 134 were affected by hematological malignancies including NHL, MM, HD and AML. The CMV screening study was carried out in 105/136 patients (77%). In this group the median number of CD34 + × 10 6 /kg infused was 10.35 (range 2-50.2) (P = 0.0014). Patients in both groups were transplanted with a variety of high-dose conditioning regimens not including total body irradiation. No patient required steroid therapy for regimen-related toxicities. Thirty-two patients after CD34-selected PBSC transplantation received G-CSF 5 g/kg post transplant while in the group of patients submitted to unfractionated PBSC, G-CSF was not used as for institutional policy. All patients who were serologically positive for herpes simplex virus (100% in both groups) received acyclovir 500 mg/m 2 every 8 h from day −1 to day 100 after transplantation. Patients were switched to oral high-dose acyclovir as soon as possible after autotransplantation. Antiviral therapy with gancyclovir or foscarnet was administered for documented CMV infection. Treatment with cidofovir or ribavirin was instituted when a documented adenovirus infection was diagnosed.
No significant differences were observed for neutrophil engraftment in both groups (13 vs 13 days) while platelet (21 vs 12 days, P = 0.0001) and reticulocyte (15 vs 12, respectively, P = 0.0001) engraftment were significantly delayed after CD34-selected PBSC transplantation producing a significantly higher requirement for platelet and RBC transfusions. The absolute number of lymphocytes and the count of CD4 + lymphocytes was significantly lower at 30 and 60 days in CD34-selected patients as reported elsewhere. 4 Five patients (12.5%) developed CMV infection between days +4 to +28 after infusion of CD34-selected PBSC, one patient (2.5%) developed CMV enteritis and five additional patients (12.5%) developed adenovirus infection (hemorrhagic cystitis or enteritis). No patient developed CMV pneumonia and no CMV or virus-related deaths were encountered. In the group of patients submitted to unfractionated PBSC, CMV disease and infection were absent and adenovirus or other viruses were not isolated within the first 100 days after reinfusion.
The incidence of CMV infection and disease was significantly higher in our CD34-selected patients as well as the incidence of adenovirus-associated disease (P = 0.0001 and P = 0.005, respectively). We do agree with the data showed by Holmberg et al and the data altogether are con-sistent with an increased risk of viral complication after CD34 selection in patients with hematological malignancies. Prolonged lymphopenia immediately after transplantation and the delayed and incomplete recovery of immune function particularly of T cell lineage 2 might induce an increased susceptibility to CMV but also to other viruses by analogy with what is observed after T cell depletion. 5 Viral surveillance is mandatory in our experience together with weekly monitoring of CMV antigenemia in an attempt to limit viral spreading and allowing successful pre-emptive treatment in patients submitted to CD34-selected PBSC transplantation. 
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Autologous PBSCT in patients with cardiac amyloidosis
We read with interest the recent review by Gertz et al, 1 expressing concern about patient selection and toxicity of high-dose therapies (HDT) for patients with primary amyloidosis. Whilst we agree on many points, we would argue that measures taken to modify treatment-related morbidity and mortality, as illustrated in our following case report, may extend the applicability of HDT to poor risk patients.
Our patient, a 57-year-old male, presented with symptomatic cardiac failure which required treatment with diuretics and angiotensin converting enzyme inhibitor for 3 months prior to autologous HDT. A cardiac biopsy showed amyloid and echocardiography showed poor diastolic function as indicated by a left ventricular end diastolic pressure of 28 mmHg. His ejection fraction was 37%. A serum IgG lambda paraprotein (total IgG 18.3 g/l) was present as were trace amounts in the urine (urine protein 0.01 g/l) but a bone marrow aspirate and trephine biopsy did not show increased plasma cells or evidence of amyloidosis. Renal function was normal. Asymptomatic hepatomegaly was present with a raised bilirubin (50 mol/l, normal Ͻ21) and a raised alkaline phosphatase (262 IU/l, normal Ͻ120) and hepatic biopsy confirmed amyloidosis. No gastrointestinal or neurological symptoms were present and biopsies of these and other organs were not performed. These features were diagnostic of primary amyloid with predominant cardiac manifestations but involvement of at least two major organ systems, predictive of both a poor prognosis without specific treatment and of high morbidity and mortality following HDT. Our patient was also a low priority candidate for cardiac allograft and we proceeded to autologous HDT following advice from Dr Comenzo that we should consider elective patient admission to our intensive therapy unit.
Our patient was mobilised with G-CSF alone, requiring two attempts at doses of 10 g/kg and 16 g/kg with multiple aphereses collecting in total 3.5 × 10 6 CD34 + cells/kg. On day −3 the patient was admitted to ITU where a SwanGanz catheter was inserted to measure atrial filling pressure and cardiac output. As atrial distension is a potential cause of supraventricular tachycardias we used atrial filling pressures as a guide for intravenous fluid administration. After an intravenous fluid challenge of 500 ml over 1 h high-dose melphalan (200 mg/m 2 ) was given fractionated over 2 days (days −3, −2) with 3 litres of fluid per day, as recent reports have questioned the need for forced diuresis after high-dose melphalan therapy. 2, 3 This was tolerated well and it was planned to fractionate DMSO cryopreserved stem cell infusions (9 bags per day) over 2 days on days 0, +1, after prophylactic amiodarone administration and modified fluid intake of 3 litres per day. However, 20 min after stem cell infusion on day 0 our patient developed cardiogenic shock which was recognised promptly and managed by discontinuation of amiodarone and treatment with dobutamine, midazolam and morphine infusions, the patient recovering slowly over the next 24 h. In view of this experience, the second planned stem cell infusion was abandoned and to hasten neutrophil recovery (CD34 + cells infused = 1.7 × 10 6 /l), G-CSF 300 g/day was given from days +4 to +14. The Swanz-Ganz catheter was removed on day +1 and the patient transferred to the bone marrow transplant ward, where the post-transplant course was marked by fluid overload responsive to diuretic therapy, severe nausea, vomiting and a single episode of uncomplicated neutropenic fever associated with Gram-positive bacillus infection. Neutrophils reached 0.5 × 10
